Table 1.
Study charcteristics & patient demographics.
| Author | LOE | PRP | N PRP | Female (%) | Age ± SD (Yrs) | Control | N Control | Female (%) | Age ± SD (Yrs) | F/U (Mo) | Risk of Bias |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Atwa et al., 2018 | II | PRP | 18 | 16 (88.9%) | 38.5 ± 8.0 | CS | 18 | 16 (88.9%) | 36.6 ± 8.8 | 3 | High |
| Güven et al., 2019 | II | PRP & Splint | 20 | N/R | 47.5 | Splint | 20 | N/R | 50 | 1 | High |
| Malahias et al., 2018 | I | PRP US | 26 | N/R | 60.5 ± 14.4 | NS | 24 | N/R | 57.2 ± 16.1 | 3 | Low |
| Raeissadat et al., 2018 | I | PRP & Splint | 21 | 21 (100%) | 51.2 ± 9.8 | Splint | 20 | 20 (100%) | 47.2 ± 7.1 | 3 | High |
| Senna et al., 2019 | I | PRP US | 43 | 35 (81.4%) | 38.3 ± 6.4 | CS US | 42 | 36 (85.7%) | 40.7 ± 9.4 | 3 | Moderate |
| Shen et al., 2019 | I | PRP US | 26 | 25 (96.2%) | 56.8 ± 1.7 | Dex | 26 | 22 (82.6%) | 58.5 ± 2.1 | 6 | High |
| Uzun et al., 2017 | II | PRP | 20 | 16 (80%) | 48.8 ± 5.8 | CS | 20 | 16 (80%) | 48.5 ± 6.1 | 6 | High |
| Wu et al., 2017 | I | PRP US | 30 | 27 (90%) | 57.9 ± 1.5 | Splint | 30 | 25 (83.3%) | 54.3 ± 1.3 | 6 | High |
CS; Corticosteroid, Dex; Dextrose, F/U; Follow-Up, Mo; Months, N; Number, NS; Normal Saline, PRP; Platelet Rich Plasma, SD; Standard deviation, Yrs; Years.